Abstract:BACKGROUND:The incidence of pulmonary embolism (PE) in lung cancer patients who underwent surgery increased during the perioperative period, and prophylactic anticoagulation therapy was important part of enhanced recovery after surgery (ERAS). However, the timing of preventive anticoagulation in patients with lung cancer remained controversial. This study was designed to investigate the safety and efficacy of perioperative prophylactic anticoagulation therapy for lung cancer patients.METHODS:Retrospective research was conducted on 562 lung cancer patients who underwent video-assisted thoracoscopic (VATS) anatomic pulmonary resections in West China Hospital from June 2016 to December 2016. 56 patients were treated with low molecular weight heparin (LMWH) anticoagulation 12 hours before operation until discharge, while the other 506 patients were treated with LMWH 24 hours after operation until discharge. The postoperative chest drainage volume, postoperative bleeding, pulmonary embolism incidence, and respiratory complications were analyzed.RESULTS:(1) There were no significant differences in prothrombin time (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) between the pre-operation prophylactic anticoagulation group (PRE group) [(11.5±3.9) s, (27.8±3.5) s, (0.96±0.06) s] and the post-operation prophylactic anticoagulation group (POST group) [(11.4±1.4) s, (28.3±4.0) s, (0.98±0.07) s] (P=0.796, P=0.250, P=0.137), and there was no significant difference in Caprini score between the PRE group (3.1±1.8) and the POST group (3.3±1.5) (P=0.104). (2) There were no significant differences in anesthesia time and intraoperative bleeding between PRE group [(130.2±53.9) min, (76.8±49.3) mL] and POST group [(142.2±56.5) min, (73.7±41.6) mL] (P=0.067, P=0.201). (3) The total drainage volume in 72 hours after operation in PRE group [(728.1±505.7) mL] was significantly higher than that of POST group [(596.4±373.5) mL] (P=0.005), while there were no significant differences between the two groups in total postoperative drainage volume [(1,066.8±1,314.6) mL vs (907.8±999.8) mL, P=0.203]. (4) There were no significant differences between the two groups in pulmonary embolism incidence (1.785% vs 0.019%, P=0.525) and postoperative bleeding rates (1.785% vs 0.039%, P=0.300). (5) There were no significant differences between PRE group and POST group in subcutaneous emphysema incidence (1.785% vs 1.581%, P=0.989) and pulmonary infection rates (14.285% vs 6.324%, P=0.085).CONCLUSIONS:The clinical value of preoperative prophylactic anticoagulation is equal to postoperative prophylactic anticoagulation for lung cancer patients.

Comparison of Clinical Efficacy of Thrombolysis and Pure Anticoagulation Therapy in the Initial Treatment of Cancer Patients with High Risk Pulmonary Embolism before Surgery

Incidence of Venous Thromboembolism and Hemorrhage in Chinese Patients after Pulmonary Lobectomy: Mechanical Prophylaxis or Mechanical Prophylaxis Combined with Pharmacological Prophylaxis: a Randomized Controlled Trial.

Clinical Analysis of Patients with Saddle Pulmonary Embolism and Its Comparison with the Main Pulmonary Artery Embolization

Comparison of Efficacy of Different Treatments for Pulmonary Embolism

Clinical Value Evaluation of Perioperative Prophylactic Anticoagulation Therapy for Lung Cancer Patients

Analysis of the Clinical Treatment of Pulmonary Thromboembolism in Two Medical Centers

Treatment of Pulmonary Embolism:An Analysis of 128 Cases

Comparison of the Outcomes Among Different Treatment of Pulmonary Embolism

Association Between the Use of Pre- and Post-thrombolysis Anticoagulation With All-Cause Mortality and Major Bleeding in Patients With Pulmonary Embolism

Perioperative Pharmacological Thromboprophylaxis in Patients with Cancer: A Systematic Review and Meta-analysis.

Pulmonary Embolism Following Thoracotomy for Lung Cancer

Effect of Low Molecular Weight Heparin on Venous Thromboembolism Disease in Thoracotomy Patients with Cancer.

Thrombolytic and Anticoagulant Therapy for Acute Submassive Pulmonary Embolism.

Clinical Analysis of Pulmonary Embolism in Malignant Tumors of 198 Cases

Comparison of the Efficacy and Safety of Rivaroxaban and Low-Molecular-weight Heparin in Chinese Lung Cancer Patients with Nonhigh-Risk Pulmonary Embolism

The efficacy of low molecular weight heparin in sixty cancer patients with venous thromboembolism

Clinical Analysis of 106 Cases Pulmonary Embolism

[Multicenter Clinical Trial on the Efficacy of Thrombolytic Therapy with Urokinase And/or Anticoagulant with Low Molecular Weight Heparin in Acute Pulmonary Embolism].

Efficacy of interventional therapy on acute pulmonary embolism

Experience of Interventional Thrombolysis Therapy for Massive Pulmonary Thrombosis Embolism after Video-assisted Thoracoscopic Surgery for Lung Cancer

Clinical analysis of 30 patients of lung cancer with pulmonary embolism